In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Investing in health for a competitive, secure, and resilient Europe: A strategic call to action
A new report from the Partnership for Health System Sustainability and Resilience EU Expert Advisory Group, supported by CRA, calls for a more strategic and...